08:45 AM EDT, 05/19/2026 (MT Newswires) -- Medicenna Therapeutics ( MDNAF ) has finalized the terms of its previously-announced marketed underwritten public offering of securities of the company, being an offering of units at a price to the public of $0.50 per unit, the company said on Tuesday.

Each unit will be comprised of one common share of the company and one half of one warrant of the company, each warrant entitling the holder thereof to acquire one common share at an exercise price of $0.65 until the date that is three years following the closing date of the offering, said the company.

The company plans to use the net proceeds primarily to advance the clinical and regulatory development of its lead programs (including MDNA11 and MDNA113), to fund working capital and for general corporate purposes.

The offering is expected to close on or around May 27, 2026, subject to the satisfaction of customary closing conditions, added the company.